Clinical Trial Update: Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pomalidomide combined with an anti-PD-1 antibody and selinexor (PPS) in relapsed/refractory primary central nervous system l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Pomalyst (pomalidomide)
• XPOVIO (selinexor)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING